眼部移植物抗宿主病的研究进展

Current research on ocular graft-versus-host disease

造血干细胞移植（SCT）是治疗恶性血液疾病的可靠疗法,SCT之后罹患移植物抗宿主病（GVHD）是患者致残和死亡的主要原因,根据其始发时间和临床表现的不同可分为急性和慢性2种.急性GVHD表现为一种累及皮肤、胃肠道和肝的特殊综合征;慢性GVHD则表现为一种多向的综合征,累及部位通常包括皮肤、口腔、肝脏、胃肠道、肺以及眼.接受同种异体造血干细胞移植之后大约40％～60％的患者会出现急性或慢性的眼部GVHD,导致几种严重眼部疾病并且极大地降低了患者的生活质量.然而到目前为止尚无各方认可的针对眼部GVHD的治疗方案出台.笔者概述了GVHD、眼部GVHD的最新研究进展和提高其治疗、预防水平的迫切性.

Hematopoietic stem cell transplantation （SCT） is a reliable treatment for malignant hematological diseases.After receiving an allogeneic SCT,graft-versus-host disease is a major cause of death and disability.Depending on the time of its origin and clinical manifestations,GVHD can be divided into acute and chronic types.Acute GVHD is defined as a syndrome involving the skin,gastrointestinal tract,and liver.Chronic GVHD is defined as a syndrome and involves organs that typically include the skin,mouth,liver,gastrointestinal tract,lungs,and eyes.After receiving allogenic hematopoietic stem cell transplants,about 40%-60% of the patients will suffer from acute or chronic graft-versus-host disease,a disease that can lead to several serious ocular diseases and greatly affects the quality of life of patients.However,guidelines for treatment have not been issued so far.This paper provides an overview of the latest research progress on ocular HVGD and emphasizes the urgency for its prevention.